ANDAORALCAPSULE
Approved
Oct 2021
Lifecycle
Post-LOE
Competitive Pressure
30/100
Data completeness
3/8 — Basic
BUTALBITAL, ASPIRIN AND CAFFEINE (butalbital, aspirin, and caffeine) by Novartis is cyclooxygenase inhibitors [moa]. Approved for nonsteroidal anti-inflammatory drug [epc]. First approved in 2021.
Drug data last refreshed 19h ago
Mechanism of Action
Cyclooxygenase Inhibitors
Pharmacologic Class:
Nonsteroidal Anti-inflammatory Drug
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Company
Novartis
BASEL, Switzerland
Worked on BUTALBITAL, ASPIRIN AND CAFFEINE at Novartis? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.